Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REJOICE-PanTumor01
2024-513307-13-00Phase 2Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of raludotatug deruxtecan in Nonhematologic neoplasms, endometrial cancer (EC), Cervical Cancer (CC) and 6 more (5 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective response rate (ORR) for all cohorts except clear cell renal cell carcinoma, Disease control rate (DCR) for clear cell renal cell carcinoma cohort and 3 more. Planned start Mar 2025; status: authorised.
02
Drugs
raludotatug deruxtecan
03
Conditions
Nonhematologic neoplasmsendometrial cancer (EC)Cervical Cancer (CC)clear cell ovarian cancerEndometrioid Cystadenocarcinoma
Beyond the preview
Go deeper on 2024-513307-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513307-13-00.